COPD therapeutic - Medestea
Latest Information Update: 01 Dec 2015
At a glance
- Originator Medestea
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Chronic obstructive pulmonary disease
Most Recent Events
- 01 Dec 2015 Clinical trials in Chronic obstructive pulmonary disease in Italy (unspecified route)